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ashville, Tennessee; Atlanta, Georgia; and Baltimore, Maryland
OBJECTIVES We sought to assess the relationship between survival, peak exercise oxygen consumption
(VO2), and heart failure survival score (HFSS) in the current era of heart failure (HF) therapy.
BACKGROUND Based on predicted survival, HF patients with peak VO2 14 ml/min/kg or medium- to
high-risk HFSS are currently considered eligible for heart transplantation. However, these
criteria were developed before the widespread use of beta-blockers, spironolactone, and
defibrillators—interventions known to improve the survival of HF patients.
METHODS Peak VO2 and HFSS were assessed in 320 patients followed from 1994 to 1997 (past era) and
in 187 patients followed from 1999 to 2001 (current era). Outcomes were compared between
these two groups of patients and those who underwent heart transplantation from 1993 to
2000.
RESULTS Survival in the past era was 78% at one year and 67% at two years, as compared with 88% and
79%, respectively, in the current era (both p  0.01). One-year event-free survival (without
urgent transplantation or left ventricular assist device) was improved in the current era,
regardless of initial peak VO2: 64% vs. 48% for peak VO2 10 ml/min/kg (p  0.09), 81%
vs. 70% for 10 to 14 ml/min/kg (p  0.05), and 93% vs. 82% for 14 ml/min/kg (p  0.04).
Of the patients with peak VO2 of 10 to 14 ml/min/kg, 55% had low-risk HFSS and exhibited
88% one-year event-free survival. One-year survival after transplantation was 88%, which is
similar to the 85% rate reported by the United Network for Organ Sharing for 1999 to 2000.
CONCLUSIONS Survival for HF patients in the current era has improved significantly, necessitating
re-evaluation of the listing criteria for heart transplantation. (J Am Coll Cardiol 2004;43:
787–93) © 2004 by the American College of Cardiology Foundations
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peart failure (HF) patients with peak exercise oxygen con-
umption (VO2) of14 ml/min/kg or a medium- to high-risk
eart failure survival score (HFSS) are currently considered
ligible for heart transplantation, based on the presumption
hat such patients will have a better survival with transplanta-
ion than with medical therapy (1–5). However, these criteria
See page 803
ere developed before the widespread use of beta-blockers,
pironolactone, and defibrillators—interventions known to im-
rove survival in HF (6–11). These criteria may therefore need
o be revised in the current era. To test this hypothesis, we
ompared the relationship between peak VO2, HFSS, and
urvival between HF patients treated from 1994 to 1997 and
hose treated from 1999 to 2001, and we compared their
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or Health Services Research, and ‡Center for Education and Research in Therapeu-
ics, Vanderbilt University Medical Center, Nashville, Tennessee; §Cardiology
ivision, Emory University, Atlanta, Georgia; Geriatric Research, Education, and
linical Center and ¶Medicine Service, Nashville Veterans Affairs Medical Center,
ashville, Tennessee; and the #Department of Cardiothoracic Surgery, University of
aryland, Baltimore, Maryland.
Manuscript received June 3, 2003; revised manuscript received August 23, 2003,sccepted August 26, 2003.urvival with patients who underwent heart transplantation
etween 1993 and 2000.
ETHODS
he study population consisted of HF patients with an
jection fraction40% who underwent exercise testing with
eak VO2 determination between 1994 and 1997 (past era)
nd 1999 to 2001 (current era), as part of the Vanderbilt
eart Failure Program, and patients who underwent heart
ransplantation between 1993 and 2000. Patients were
xcluded if they were taking inotropes, had angina or
rthopedic problems restricting exercise capacity, had sig-
ificant valvular stenosis, or exhibited oxygen desaturation
uring exercise. A total of 320 patients from the past era,
87 patients from the current era, and 184 patients who
nderwent transplantation were studied. Heart failure pa-
ients within each era were classified a priori, based on peak
O2, into three groups: group 1  10 ml/min/kg; group 2
10 to 14 ml/min/kg; and group 3  14 ml/min/kg.
imilarly, the HFSS was calculated for all patients, as
escribed in the original investigation, using the following
ariables: etiology, heart rate, ejection fraction, mean blood
ressure, intraventricular conduction delay, peak VO2, and
erum sodium (12). Based on the HFSS, these patients were
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igh-risk (7.19) groups.
Patients exercised on a Marquette treadmill, per the modi-
ed Naughton protocol, and were connected to a Medgraphics
ardio O2 combined VO2/ECG Exercise System (Medical
raphics Corp., St. Paul, Minnesota). The testing protocol
nd data interpretation have been previously described (13).
utcomes and definitions. The primary study outcome
as one-year event-free survival (without the need for a left
entricular assist device [LVAD] or urgent transplantation)
or HF patients and overall one-year survival for trans-
lanted patients. Urgent transplantation for the current era
as defined as United Network for Organ Sharing (UNOS)
tatus 1A listing at the time of transplantation. In the past
ra, urgent transplantation was defined as the presence, at
he time of transplantation, of mechanical circulatory sup-
ort with a left and/or right ventricular assist device im-
lanted 30 days or evidence of complications related to
echanical support, intra-aortic balloon pump, mechanical
entilation, or continuous infusion of high-dose intravenous
notropes or multiple intravenous inotropes with continuous
emodynamic monitoring.
tatistical analysis. Univariate analyses were performed to
ssess associations between patient characteristics and out-
omes, using the chi-square test for categorical variables and
he t test for continuous variables. The Kaplan-Meier
ethod was used to assess survival. To assess the temporal
rends in outcomes for patients undergoing transplantation,
n order to match them with the two groups of HF patients,
ransplanted patients were also classified into two groups:
hose who were transplanted between 1993 and 1997 and
hose transplanted between 1998 and 2000. Because there
as no significant survival difference between the two
roups, they were combined for further outcome compari-
ons with the HF patients.
For the overall survival analysis for HF patients, all patients
ho underwent transplantation or LVAD placement were
ensored at the time of surgery. For event-free survival analysis,
atients who underwent transplantation and did not meet the
riteria for urgent transplantation were censored.
Exploratory analyses using the chi-square test were per-
ormed among the patients in the current era to assess the
ombined impact of beta-blocker and defibrillator ther-
py on one-year outcomes and the relationship between
eak VO2 and HFSS. All analyses were performed using
PSS for Windows, release 11.5 (SPSS Inc., Chicago,
Abbreviations and Acronyms
HF  heart failure
HFSS  heart failure survival score
LVAD  left ventricular assist device
UNOS  United Network for Organ Sharing
VO2  oxygen consumptionllinois).ESULTS
atient population. Baseline patient characteristics of HF
atients from the two eras are shown in Table 1. There were
o significant differences between the two groups with
espect to age, gender, race, ejection fraction, serum sodium,
ntraventricular conduction delay, and peak VO2. Patients in
he current era had, on average, a lower heart rate (74  14
eats/min vs. 88  16 beats/min, p  0.01).
Baseline medical therapy was similar, except for higher
se of beta-blockers (72% vs. 10%, p  0.01) and
pironolactone (41% vs. 2%, p  0.01) in the current era.
eta-blocker types and dosages in the current era were as
ollows: 54  33 mg atenolol (3%), 31  24 mg
arvedilol (54%), and metoprolol (43%)—108  59 mg
uccinate and 64  27 mg tartrate. Defibrillator use was
lso more common in the current era (19% vs. 11%, p 
.01). The overall use of anti-arrhythmic medications
as similar between the two eras (12% vs. 14% in the past
s. current era); however, for those with anti-arrhythmic
herapy, there was a higher proportional use of amioda-
one in the current era (82% vs. 70%, p  0.01).
able 1. Baseline Patient Characteristics
Past Era
(n  320)
Current Era
(n  187) p Value
ge (yrs) 52  11 54  11 NS
ales 74% 76% NS
aucasians 85% 85% NS
schemic etiology 52% 56% NS
jection fraction (%) 23  9 21  8 NS
eart rate (beats/min) 88  16 74  14  0.01
ean blood pressure (mm Hg) 86  11 84  12 NS
erum sodium (mEq/l) 137  4 138  4 NS
YHA class III/IV 83% 84% NS
ntraventricular conduction delay 49% 53% NS
eak exercise Vo2 (ml/min/kg)
Mean  SD 13.0  3.3 12.8  3.2 NS
10 20% 23%
10–14 45% 42% NS
14 35% 35%
FSS
High risk 18% 10%
Medium risk 37% 32%  0.01
Low risk 45% 58%
edications
ACE inhibitor 91% 93% NS
Diuretic 96% 95% NS
Digoxin 93% 93% NS
Beta-blocker 10% 72%  0.01
Spironolactone 2% 41%  0.01
Anti-arrhythmic 12% 14% NS
Defibrillator 11% 19% 0.01
VAD use 1% 3% 0.08
verall transplantation 16% 16% NS
rgent transplantation 4% 4% NS
ata are presented as the mean value  SD or percentage of patients.
ACE  angiotensin-converting enzyme; HFSS  heart failure survival score;
VAD  left ventricular assist device; NS  not significant; NYHA  New York
eart Association; VO2  oxygen consumption.For patients who underwent heart transplantation, the
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March 3, 2004:787–93 Eligibility Criteria for Heart Transplantationean age of the recipients at the time of transplantation was
2  11 years. Of the patients, 81% were males, and 95%
ere white. The mean age of the donors was 29  12 years.
he average donor ischemic time was 181  56 min.
utcomes. The mean follow-up period for the past-era
roup was 311 213 days; current era, 376 268 days; and
ost-transplant group, 1,260  854 days. Three patients in
he past era and six in the current era underwent LVAD
lacement. A total of 52 patients in the past era and 22 in
he current era died, and 40 patients who underwent
ransplantation died during the follow-up period. In the
ast era, 51 patients underwent heart transplantation, 12
f whom met the criteria for urgent transplantation.
n the current era, 29 patients underwent heart trans-
lantation, 8 of whom met the criteria for urgent
ransplantation.
igure 1. Cumulative survival for patients in the past era and current era d
n initial higher mortality rate after transplantation, overall one-year surviva
eart failure therapy in the past era.
igure 2. Improvement in one-year event-free survival was noted for patie
onsumption (VO2) groups. Patients with a high-risk heart failure surviv
ntermediate-risk peak VO2 group was comparable to that after transplanta
rogram. §One-year post-transplant survival. #United Network for Organ ShaSurvival curves for the three groups are compared in
igure 1. Overall survival rates in the three groups (past era,
urrent era, and those who underwent transplantation,
espectively) were 78%, 88%, and 88% at one year and 67%,
9%, and 84% at two years (p  0.01).
One-year event-free survival improved in the current era,
egardless of initial peak VO2: 64% versus 48% for peak VO2
f 10 ml/min/kg (p  0.09), 81% versus 70% for peak
O2 of 10 to 14 ml/min/kg (p 0.05), and 93% versus 82%
or peak VO2 of14 ml/min/kg (p 0.04). When stratified
y HFSS, the outcomes improved the most in the current
ra for the high-risk group (64% for current era vs. 41% for
ast era, p  0.06) (Fig. 2).
Table 2 shows the distribution of patients and outcomes
ased on both peak VO2 and HFSS. Of the patients with
eak VO2 of 10 to 14 ml/min/kg, 55% had a low-risk HFSS
strates a significantly better survival for patients in the current era. After
mparable to medical therapy for patients in the current era and better than
the current era of heart failure management for all peak exercise oxygen
re (HFSS) showed the most improvement in survival. Survival for the
pen bars  past era; solid bars  current era. *Vanderbilt Heart Failureemon
l is conts in
al sco
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ring 1990 to 2000.
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Eligibility Criteria for Heart Transplantation March 3, 2004:787–93nd 88% one-year event-free survival. Similarly, 20% of
atients with a medium-risk HFSS had peak VO2 of
14 ml/min/kg and demonstrated 85% one-year event-free
urvival.
Figure 3 shows the event-free one-year outcomes for
atients with intermediate-risk peak VO2 and a medium-
isk HFSS, based on beta-blocker therapy and use of a
efibrillator. Both groups had survival comparable to one-
ear survival after heart transplantation (88%) if the patients
ad a defibrillator and were taking beta-blockers.
ISCUSSION
he primary objective of heart transplantation is to improve
urvival and functional capacity. Consequently, patients are
isted for transplantation only when it is presumed that they
ill live longer and function better after transplantation than
hey would with medical therapy. A variety of criteria has been
eveloped in an attempt to identify such patients. The most
idely utilized criteria are based on peak VO2 and HFSS, a
coring system based on seven parameters, including peak VO2
12,14). Specifically, peak VO2 of 14 ml/min/kg or a
edium- to high-risk HFSS is thought to identify patients
ho will have a survival benefit with heart transplantation
1–5). The validity of these criteria has not been reassessed
ince the initial recommendations. Recently, several new HF
herapies have been introduced (e.g., beta-blockers, spirono-
actone, cardiac defibrillators), all of which improve survival
6–11). There continues to be a shortage of donor organs,
eading to long waiting times and high mortality rates for
atients awaiting transplantation (15,16). This necessitates that
he available organs should be allocated to the patients at
ighest risk of dying, underscoring the importance of accurate
rognosis determination.
Our data show that in the current era of HF manage-
ent, the prognosis of patients has improved significantly,
uggesting that the strategy for transplant candidate selec-
ion needs reassessment. Mancini et al. (14) demonstrated
hat HF patients with peak VO2 of 14 ml/min/kg have a
ne-year combined mortality or urgent transplantation rate
f 50%, leading to a general recommendation that these
atients should be evaluated for transplantation (1–5,14).
able 2. One-Year Event-Free Survival in the Current Era
ased on Peak Oxygen Consumption and Heart Failure Survival
core
HFSS
Peak Exercise VO2 (ml/min/kg)
<10 10–14 >14
n
Survival
(%) n
Survival
(%) n
Survival
(%)
igh risk 9 56 8 63 2 100
edium risk 18 58 27 74 13 85
ow risk 15 75 43 88 51 96
bbreviations as in Table 1.ecause peak VO2 is linearly related to HF prognosis, an flternate approach is to use it as continuous variable (17).
aronson et al. (12) used this approach and incorporated
ther risk predictors to create a risk assessment model called
he HFSS, which is now an alternate tool used to select
eart transplant candidates. Because of these earlier reports,
anagement of patients with advanced HF has undergone
ajor changes that not only impact overall survival but also
he relationship between peak VO2 or HFSS and survival.
or example, beta-blockers improve survival but do not alter
eak VO2 significantly (6). A benefit from defibrillators is
lso independent of changes in exercise tolerance. More-
ver, beta-blockers also affect physiologic variables that
onstitute the HFSS (e.g., heart rate and mean blood
ressure), thus modifying the HFSS calculation. It is
herefore not surprising that beta-blocker therapy influences
F prognostic variables and that for every level of exercise
olerance, beta-blocker therapy may improve outcomes
18,19).
Similarly, our data indicate that in the current era of HF
anagement, although peak VO2 continues to be an impor-
ant predictor, the prognosis of patients with similar values
as improved considerably, as compared with the past era.
ven when LVAD and urgent transplantation were consid-
red as “events,” along with death, one-year event-free
urvival was 81% for patients with peak VO2 of 10 to
4 ml/min/kg and increased to 86% for those patients who
ere on beta-blockers and had a defibrillator. These results
re comparable to one-year post-transplant survival of 85%,
n average, and demonstrate that for patients with
ntermediate-risk peak VO2 in the current era, medical
herapy offers a survival benefit similar to heart transplan-
ation (16).
If mortality rates are similar, should patients be trans-
lanted to improve quality of life? Symptoms and the
ospitalization rate improve significantly for HF patients
reated with beta-blockers, whereas observational data sug-
est significant continued medical and psychological prob-
ems after transplantation (20–22). Considering the signif-
cantly improved morbidity and mortality of HF patients
ith medical therapy, it is not surprising that a transplant
enefit is shown to be mostly restricted to the highest risk
atients, and a randomized trial comparing medical therapy
ith transplantation has been suggested (23,24).
Current guidelines recommend that patients with peak
O2 of 10 to 14 ml/min/kg or a medium-risk HFSS should
e considered for transplantation, thus tacitly equating the
wo groups of patients. However, there is a significant
iscordance between the two. Of the patients with peak VO2
f 10 to 14 ml/min/kg, 55% had a low-risk HFSS and 88%
ne-year event-free survival. Conversely, 22% of patients
ith a medium-risk HFSS had peak VO2 of  14 ml/
in/kg and demonstrated 85% one-year event-free survival.
herefore, intermediate-risk groups identified by either
ethod include a sizeable portion of patients with an
xpected good prognosis on medical therapy alone. Identi-
ying these patients can substantially impact the transplant
l
p
m
H
p
u
V
h
p
H
m
s
p
s
t
t
m
t
v
c
Y
i
t
d
d
H
H
s
h
t
h
m
m
f
f
4
p
p
m
I
c
1
t
F
p
h
F
s
791JACC Vol. 43, No. 5, 2004 Butler et al.
March 3, 2004:787–93 Eligibility Criteria for Heart Transplantationist, considering that in our study, 78 (42%) of 187 of
atients in the current era had peak VO2 between 10 and 14
l/min/kg and 58 (31%) of 187 patients had a medium-risk
FSS.
Peak VO2 alone accurately predicted low- and high-risk
atients, similar to a more comprehensive HFSS. However,
nlike the favorable prognosis of intermediate-risk peak
O2 patients, the medium-risk HFSS patients, as a group,
ad 71% one-year event-free survival, identifying a group of
atients who are likely to benefit from transplantation.
owever, HFSS in our study did not differentiate between
edium- and high-risk patients. As mentioned earlier, a
izeable portion of patients with a medium-risk HFSS had
reserved peak VO2 and, in turn, a better prognosis. When
tratified by beta-blockers and defibrillator use, these pa-
ients had 90% one-year event-free survival when both
herapies were used. Finally, beta-blockers therapy, in itself,
ay effect the calculation and, in turn, possibly the calibra-
ion of HFSS, as it impacts several of its constituent
ariables. This is demonstrated by the fact that despite a
omparable ejection fraction, sodium concentration, New
ork Heart Association functional class, prevalence of
ntraventricular conduction delay, and peak exercise VO2,
igure 3. One-year event-free survival in the current era for the intermediat
atients with both therapies simultaneously to be comparable to that after tran
eart failure survival score (HFSS). Open bars no beta-blocker therapy; dott
igure 4. Suggested algorithm for selection of patients for heart transplan
core.he distribution of patients in the three HFSS groups was
ifferent in the current versus past era. Thus, for a similar
egree of HF burden, patients are likely to have a different
FSS calculation now. All of these features suggest that
FSS in the current era needs to be modified to better
tratify risk across the HF spectrum.
Overall, patients with peak VO2 of 10 to 14 ml/min/kg
ad survival rates that were comparable to those after
ransplantation; however, some patients in this group may
ave a worse prognosis. As shown in Table 2, however, the
ajority of patients with peak VO2 between 10 and 14 ml/
in/kg actually have a low-risk HFSS and can safely be
ollowed on medical therapy alone. One possible algorithm
or selection of transplant candidates is suggested in Figure
. Using this approach, one can possibly reduce the trans-
lant list by approximately one-third without jeopardizing
atient outcomes. Alternatively, newer prognostic schemes
ay be developed using different markers.
Our recommendations are based on one-year outcomes.
t is possible that HF patients may have worse outcomes, as
ompared with transplantation, in the longer run (over 5 to
0 years), especially considering that the mortality rate after
ransplantation is highest in the first year after transplanta-
groups stratified by beta-blockers and defibrillator therapy shows survival in
ation. p 0.2 for peak exercise oxygen consumption (VO2) and p 0.07 for
rs beta-blocker therapy; solid bars beta-blocker and defibrillator therapy.
, using peak exercise oxygen consumption (VO2) and heart failure survivale-risk
splant
ed batation
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Eligibility Criteria for Heart Transplantation March 3, 2004:787–93ion but decreases significantly thereafter. However, an
lternate approach would be to continue medical therapy for
atients who have a good short-term prognosis and, if and
hen their disease progresses to the point where short-term
utcomes are likely to be worse than transplantation, then to
roceed with evaluation and listing. Because medical ur-
ency at the time of transplantation has only a mild impact
n post-transplant mortality (first-year post-transplant sur-
ival 84.8  0.7% vs. 87.4  1.0% for status 1 vs. status 2),
t may be feasible to pursue such an approach (1). Many of
hese patients are likely to remain stable for long periods of
ime, obviating the need for transplantation; some may
ever need it. Ongoing periodic reassessments should iden-
ify the group of patients who continue to deteriorate on
edical therapy in order to evaluated and listed for a
ransplant in a timely manner.
tudy limitations. There are several limitations to our
tudy. First, the HF patients from the two eras were similar
n terms of multiple clinical characteristics (e.g., age, gender,
ace, ejection fraction, serum sodium, intraventricular con-
uction delay, peak VO2); therefore, we could compare
utcomes between these groups. On the contrary, trans-
lanted patients are a distinct group that may or may not be
irectly compared to the HF patients with respect to
utcomes. Patients who were transplanted may represent a
roup that was sicker than the average HF patients, making
heir improved outcomes, compared with conventional HF
reatment, even more impressive in the long run. On the
ther hand, the transplanted patients may represent a
arefully selected group of HF patients with less comorbid-
ty burden and, in turn, a better expected prognosis. Hence,
n the absence of a prospectively designed trial, direct
omparison between an average HF group of patients and
hose who get transplanted has inherent limitations. Other
imitations include the fact that this is a single-center
xperience with retrospective data collection. Not all eligible
atients were on beta-blockers at recommended doses in the
urrent era. There were only four patients who had a
iventricular pacemaker placed. The use of beta-blockers,
efibrillators, and biventricular pacemakers is expected to
ncrease in the future. It remains unknown how these trends
ould impact our results. Similarly, there may be differences
n outcomes between different types of pacemakers, and we
o not have the information on the overall use and type of
acemakers in our patients, except for those who received
iventricular pacemakers (25). Finally, our study only ad-
resses survival and does not assess quality of life for patients
ndergoing medical therapy versus transplantation.
onclusions. Our study shows that the prognosis of HF
atients has significantly improved in the current era of
herapy. Many patients with intermediate risk now have
urvival comparable to that after transplantation. These
rends are likely to continue to improve as newer therapies
re discovered and current therapies are more widely uti-
ized. These data suggest that the evaluation and listingriteria for heart transplantation in the current era need
e-evaluation.
eprint requests and correspondence: Dr. Javed Butler, Cardio-
ogy Division, 383 PRB, Vanderbilt University Medical Center,
ashville, Tennessee 37232-6300. E-mail: javed.butler@
anderbilt.edu.
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